Business
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
BOSTON & DAEJEON, South Korea, April 13, 2026--Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
About this update from Orum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":228,"url":"https://media.zenfs.com/en/business-wire.com/23ce5cd444d0e71a38a63cb3822ae4b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8fI72uze0CuxZ.zTsgm8Kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ1Ng--/https://media.zenfs.com/en/business-wire.com/23ce5cd444d0e71a38a63cb3822ae4b1","width":480,"height":228}},"lazy":false},{"type":"text","content":"Appointments add clinical development, translational oncology, company-building, and strategic investment expertise as Orum advances its next wave of degrader-antibody conjugate programs","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & DAEJEON, South Korea, April 13, 2026—(BUSINESS WIRE)—Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board of Directors, following approval at the Company’s Annual General Meeting, which took place March 27, 2026. Orum is advancing GSPT1-directed TPD²® programs and developing novel degrader payloads to expand the potential of DACs in oncology and beyond.","length":574,"tagName":"p"},{"type":"text","content":""Maria and Geoff join Orum at an important point in the Company’s evolution," said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. "As we advance our next wave of DAC programs to the clinic and continue to broaden our payload capabilities, their perspectives will be highly valuable. Maria brings deep experience across oncology clinical development, translational medicine, biomarker strategy, and regulatory execution. Geoff brings a strong record in company building, partnering, and strategic transactions across the life sciences. Together, they strengthen our Board as we continue building Orum into a leading DAC company."","length":652,"tagName":"p"},{"type":"text","content":""Orum has built a compelling approach to targeted protein degradation by combining the precision of antibodies with the catalytic potential of degrader payloads," said Dr. Koehler. "I am pleased to join the Board as the company advances its DAC pipeline to the cli...